Clinical Trial Update: Tumor and Vaccine Site With a Toll Like Receptor (TLR) Agonist [Phase 2]

View source ↗

Summary

Phase 2 trial update for a tumor and vaccine site using a Toll-Like Receptor agonist in melanoma; study completed with results posted.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Melanoma

Snippet

Sponsor: M.D. Anderson Cancer Center | Conditions: Melanoma | Phase 2 | Status: COMPLETED | Results posted: 2021-08-13